Associations between family history of Parkinson's disease and dementia and risk of dementia in Parkinson's disease: A community-based, longitudinal study

Movement Disorders

Volumn 21, Issue 12, 2006, Pages 2170-2174

  Kurz, Martin Wilhelm ^a,b   Larsen, Jan Petter ^b   Kvaloy, Jan Terje ^b   Aarsland, Dag ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b STAVANGER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Dementia; Family history; Genetics; Parkinson's disease; Pathogenesis

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMENTIA; FAMILIAL DISEASE; FAMILY HISTORY; FEMALE; FOLLOW UP; HEREDITY; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; NORWAY; ONSET AGE; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RELATIVE; RISK ASSESSMENT;

AGE OF ONSET; AGED; AGED, 80 AND OVER; DEMENTIA; FAMILY HEALTH; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PROPORTIONAL HAZARDS MODELS; RESIDENCE CHARACTERISTICS; RISK; RISK FACTORS; TIME FACTORS;

EID: 33846446384     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21144     Document Type: Article

References (39)

1. Eriksen JL, Wszolek Z, Petrucelli L. Molecular pathogenesis of Parkinson disease. Arch Neurol 2005;62:353-357.
2. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005;20: 1255-1263.
3. Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387-392.
4. Aarsland D, Larsen JP, Tandberg E, et al. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 2000;48:938-942.
5. Levy G, Tang MX, Louis ED, et al. The association of incident dementia with mortality in PD. Neurology 2002;59:1708-1713.
6. Marechal L, Campion D, Hannequin D. [Familial forms of Alzheimer's disease]. Presse Med 2003;32:756-763.
7. Zhang P, Wang L, Yang Z, et al. [Associated genes for dementia of the Alzheimer type]. Yi Chuan 2003;25:445-449.
8. Aarsland D, Perry R, Brown A, et al. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 2005;58:773-776.
9. Braak H, Rub U, Jansen Steur EN, et al. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005; 64:1404-1410.
10. Jellinger KA, Seppi K, Wenning GK, et al. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm 2002;109:329-339.
11. Mayeux R, Ottman R. Alzheimer's disease genetics: home runs and strikeouts. Ann Neurol 1998;44:716-719.
12. Strittmatter WJ, Weisgraber KH, Huang DY, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:8098-8102.
13. Morris HR. Genetics of Parkinson's disease. Ann Med 2005;37: 86-96.
14. Marder K, Tang MX, Cote L, et al. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol 1995;52:695-701.
15. Scarmeas N, Hadjigeorgiou GM, Papadimitriou A, et al. Motor signs during the course of Alzheimer disease. Neurology 2004;63: 975-982.
16. Tandberg E, Larsen JP, Nessler EG, et al. The epidemiology of Parkinson's disease in the county of Rogaland, Norway. Mov Disord 1995;10:541-549.
17. Larsen JP, Dupont E, Tandberg E. Clinical diagnosis of Parkinson's disease. Proposal of diagnostic subgroups classified at different levels of confidence. Acta Neurol Scand 1994;89:242-251.
18. Kurz M, Alves G, Aarsland D, et al. Familial Parkinson's disease: a community-based study. Eur J Neurol 2003; 10: 159 -163.
19. Fahn S, Elton RL, Committee MotUD. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Liebermann A, editors. Recent Development in Parkinson's Disease. Florham Park, NJ: Macmillan Health Care Information; 1987. p 153-163.
20. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
21. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (revised). 3rd ed. Washington, DC: APA; 1987.
22. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the mental state of patients for the clinician. J Psychiatr Res 1975;12:189.
23. Mattis S. Dementia Rating Scale. In: Bellak L, Karasu LTB, editors. Geriatric Psychiatric. A Handbook for Psychiatrists and Primary Care Physicians. New York: Grune & Stratton; 1976. p 893-902.
24. Inzelberg R, Schecthman E, Paleacu D, et al. Onset and progression of disease in familial and sporadic Parkinson's disease. Am J Med Genet A 2004;124:255-258.
25. Marder K, Levy G, Louis ED, et al. Familial aggregation of early-and late-onset Parkinson's disease. Ann Neurol 2003;54:507-513.
26. Levy G, Louis ED, Mejia-Santana H, et al. Lack of familial aggregation of Parkinson disease and Alzheimer disease. Arch Neurol 2004;61:1033-1039.
27. Li J, Uversky VN, Fink AL. Conformational behavior of human alpha-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T. Neurotoxicology 2002;23:553-567.
28. Kotzbauer PT, Giasson BI, Kravitz AV, et al. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation. Exp Neurol 2004;187:279-288.
29. Greenbaum EA, Graves CL, Mishizen-Eberz AJ, et al. The E46K mutation in alpha-synuclein increases amyloid fibril formation. J Biol Chem 2005;280:7800-7807.
30. Pandey N, Schmidt RE, Galvin JE. The alpha-synuclein mutation E46K promotes aggregation in cultured cells. Exp Neurol 2006; 197:515-520.
31. Kurz M, Schlitter AM, Larsen JP, et al. Familial occurrence of dementia and Parkinsonism. A systematic review. Dement Geriatr Cogn Disord 2006;22:288-295.
32. Marder K, Maestre G, Cote L, et al. The apolipoprotein epsilon 4 allele in Parkinson's disease with and without dementia. Neurology 1994;44:1330-1331.
33. Harhangi BS, de Rijk MC, van Duijn CM, et al. APOE and the risk of PD with or without dementia in a population-based study. Neurology 2000;54:1272-1276.
34. Parsian A, Racette B, Goldsmith LJ, et al. Parkinson's disease and apolipoprotein E: possible association with dementia but not age at onset. Genomics 2002;79:458-461.
35. Li YJ, Hauser MA, Scott WK, et al. Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology 2004;62: 2005-2009.
36. Wakabayashi K, Kakita A, Hayashi S, et al. Apolipoprotein E epsilon4 allele and progression of cortical Lewy body pathology in Parkinson's disease. Acta Neuropathol (Berl) 1998;95:450-454.
37. Huang X, Chen P, Kaufer DI, et al. Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch Neurol 2006;63:189-193.
38. Elbaz A, McDonnell SK, Maraganore DM, et al. Validity of family history data on PD: evidence for a family information bias. Neurology 2003;61:11-17.
39. Marder K, Levy G, Louis ED, et al. Accuracy of family history data on Parkinson's disease. Neurology 2003;61:18-23.